Insulet Corporation Q1 FY2026 earnings call

Management highlighted innovation as the core driver, international business delivered strong growth with 45% constant currency revenue growth, appointed Mike Panos as Chief Commercial Officer, made progress in market development and global manufacturing and operations, and addressed medical device correction in March.

US Omnipod revenue grew 28% in Q1, international Omnipod revenue grew 45%, total company revenue grew 30% y-o-y. Adjusted operating margin expanded 110 basis points year over year, and adjusted EPS growth was approximately 40% driven by strong top line growth and margin expansion.

Raised full-year 2026 total company revenue growth guidance from 20%-22% to 21%-23%. Q2 Omnipod revenue expected to grow 21-23%, full-year Omnipod revenue expected to grow 22-24%.

Risks include complexity in manufacturing sophisticated disposable electromechanical devices, competition in the market, and foreign exchange fluctuations.

Q: David Roman asked about strategic observations and financials; A: Ashley responded on innovation, international, commercial engine, operations and people.

Q: Robbie Marcus followed up on growth deceleration; A: Flavia explained currency impact and future catalysts.

Q: Travis Steed asked about Type 2 retention; A: Ashley and Eric discussed Type 2 momentum and retention.

Q: Larry Vigelson asked about competition impact; A: Ashley stated category expansion offsets share loss.

Q: Matthew O'Brien asked about pharmacy channel and recall; A: Ashley addressed pricing and medical device correction.

Q: Jeff Johnson asked about pricing and Type 2 retention; A: Ashley confirmed net pricing and explained Type 2 retention.

Q: Jason Bedford asked about international growth; A: Flavia explained deceleration in international growth.

Q: Shagan Singh asked about revenue shift and commercial; A: Ashley elaborated on revenue shift and commercial efforts.

Q: Matt Taylor asked about Omnipod 6; A: Ashley talked about Omnipod 6's impact on growth.